A Retrospective Analysis of the Use of 3-Factor Prothrombin Complex Concentrates for Refractory Bleeding After Cardiopulmonary Bypass in Children Undergoing Heart Surgery: A Matched Case-Control Study

2020 ◽  
Vol 24 (3) ◽  
pp. 227-231 ◽  
Author(s):  
Andrea D. Harris ◽  
Richard M. Hubbard ◽  
Rebecca M. Sam ◽  
Xu Zhang ◽  
Jorge Salazar ◽  
...  

The 3-factor prothrombin complex concentrate (3FPCC) may be used off-label to treat refractory bleeding during cardiac surgery in children. This retrospective study examined the rate of clinical complications following the use of 3FPCC. Patients treated with 3FPCC were matched to controls for age, gender, prematurity, weight, cardiopulmonary bypass times, and cross-clamp times. Fifty-nine cases were individually matched to 59 controls based on propensity scores. 3FPCC was not associated with an increased risk of thromboembolic events, mortality, or need for postoperative extracorporeal membrane oxygenator support. These results suggest the safety of 3FPCC when used for refractory bleeding after cardiopulmonary bypass in children undergoing congenital heart surgery.

2013 ◽  
Vol 15 (7) ◽  
pp. 787-794 ◽  
Author(s):  
Kuan-Yi Wu ◽  
Chia-Ming Chang ◽  
Hsin-Yi Liang ◽  
Chi-Shin Wu ◽  
Erin Chia-Hsuan Wu ◽  
...  

2021 ◽  
Author(s):  
Jiayi Zhang ◽  
Gang Wu ◽  
Hailong Zhu ◽  
Fengyuan Yang ◽  
Shuman Yang ◽  
...  

Abstract Background: The existing epidemiologic studies on the association between carnitine and breast cancer development are scarce. This study examined the association between circulating carnitine levels and breast cancer in females.Methods: This 1:1 age-matched case-control study identified 991 female breast cancer cases and 991 female controls without breast cancer. All cases and controls were confirmed with a pathological test. We measured 16 types of whole blood carnitine levels, such as free carnitine (C0) and octadecanoylcarnitine (C18), using targeted metabolomic technology. Results: The average age for cases and controls were 50.0 years (SD: 8.7 years) and 49.5 years (SD: 8.7 years), respectively. After adjusting for covariates, each SD increase in malonylcarnitine (C3DC; OR 0.91; 95% CI 0.83-1.00), decenoylcarnitine (C10:1; OR 0.87; 95% CI 0.79-0.96) and decadienoylcarnitine (C10:2; OR 0.90; 95% CI 0.82-0.99) level was associated with decreased odds of breast cancer. However, higher butyrylcarnitine (C4) levels were associated with increased risk of breast cancer (OR 1.12; 95% CI 1.02-1.23). We observed no relationship between other carnitines with breast cancer. The false discovery rates for C3DC, C4, C10:1 and C10:2 were 0.172, 0.120, 0.064 and 0.139, respectively. Conclusions: Higher levels of C3DC, C10:1, and C10:2 were protective factors for breast cancer, whereas increased C4 levels were a risk factor for breast cancer.


2001 ◽  
Vol 93 (6) ◽  
pp. 1410-1416 ◽  
Author(s):  
Gregory A. Nuttall ◽  
James A. Garrity ◽  
Joseph A. Dearani ◽  
Martin D. Abel ◽  
Darrell R. Schroeder ◽  
...  

2010 ◽  
Vol 36 (2) ◽  
pp. 130-134 ◽  
Author(s):  
H. E. Mccarthy ◽  
N. P. French ◽  
G. B. Edwards ◽  
K. Miller ◽  
C. J. Proudman

Sign in / Sign up

Export Citation Format

Share Document